Non-Small Cell Lung Cancer
Advertisement
The session covered everything from new actionable immune checkpoints to vaccines, cellular therapies, and bispecifics.
Martin Reck, MD, PhD, reflects on key updates in stage III NSCLC from the European Lung Cancer Congress 2025.
Stephen V. Liu, MD, weighs in on the data from the preplanned interim analysis that was recently published in The Lancet.
Martin Reck, MD, PhD, presented the final analysis at the European Lung Cancer Congress 2025.
Subcutaneous pembrolizumab may be “a viable treatment option" in indications where pembrolizumab is approved.
Andrea Riccardo Filippi, MD, presented survival data from the final PACIFIC-R data extraction with over 5 years of follow-up.
Suresh S. Ramalingam, MD, FACP, FASCO, presented the data during a proffered paper session at ELCC 2025.
Marina Garassino, MD, presented results from the phase 2 portion of the trial at the European Lung Cancer Congress.
The study is evaluating regimens to prevent dermatologic adverse events in patients receiving amivantamab plus lazertinib.
Myung-Ju Ahn, MD, PhD, presented data from the study during the first proffered paper session of ELCC 2025.
Nicolas Girard, MD, PhD, of Institut Curie, presented the findings from expansion cohorts of the study at ELCC 2025.
Xiuning Le, MD, PhD, presented results from the ORCHARD trial at ELCC 2025.
The award recognizes his "exceptional contributions to thoracic oncology research and education."
Amivantamab plus lazertinib showed a statistically significant improvement in OS compared with osimertinib.
Final overall survival data from the phase 3 study demonstrated significant benefits for patients with EGFR-mutated aNSCLC.
The study included patients with advanced NSCLC with PD-L1 expression of at least 50% and no EGFR, ALK, or ROS abberations.
Dr. Liu shares what he's looking forward to during the European Lung Cancer Congress, which will be held March 26-29.
Investigators of a phase 2 study uncovered a biomarker that may be associated with major pathologic response in this setting.
The multicenter, single-arm trial is evaluating the novel antibody–drug conjugate, also known as SHR-A1811.
The study investigators concluded that ivonescimab “might represent another treatment option in the first-line setting."
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.